Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects

NCT03802786 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Impairment

Interventions

DRUG: Imeglimin

Sponsor

Poxel SA